2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer
The 2015 American Thyroid Association guideline moved differentiated thyroid cancer towards less treatment: lobectomy rather than total thyroidectomy for many low-risk cancers, selective rather than routine radioactive iodine, and active surveillance for small papillary cancers.
Overview
Comprehensive guideline covering evaluation of thyroid nodules, ultrasound risk stratification, molecular testing, extent of surgery, risk stratification for recurrence, radioactive iodine indications, TSH suppression, follow-up, and management of recurrent and metastatic differentiated thyroid cancer including kinase inhibitors.
The follicular and papillary thyroid cancer pages' recommendations for lobectomy, selective iodine and surveillance of microcarcinoma follow this guideline.
- Under revision; ESTIMABL2 and IoN have since supported omitting iodine in low-risk disease.
Similar pages
not linked directly; found by shared links- Key paperSELECT: lenvatinib versus placebo in radioiodine-refractory differentiated thyroid cancer
- TermRadioiodine-refractory (RAI-R) thyroid cancer
- TechnologyThyroglobulin, calcitonin and CEA in thyroid cancer follow-up
- TechnologyRadioiodine therapy and whole-body iodine scanning
- TreatmentDabrafenib
- TreatmentSorafenib